Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease.

Kleytman, Nathaniel; Ruan, Jiapeng; Ruan, Audrey; Zhang, Bailin; Murugesan, Vagishwari; Lin, Haiqun; Guo, Lilu; Klinger, Katherine; Mistry, Pramod K.

Afiliação

Kleytman N; Yale Internal Medicine: Digestive Diseases, New Haven, CT, USA.
Ruan J; Yale Internal Medicine: Digestive Diseases, New Haven, CT, USA.
Ruan A; Yale Internal Medicine: Digestive Diseases, New Haven, CT, USA.
Zhang B; Translational Sciences, Sanofi Genzyme, Cambridge, MA, USA.
Murugesan V; Department of Rheumatology, Boston University Medical Center, Boston, MA, USA.
Lin H; Yale School of Public Health, New Haven, CT, USA.
Guo L; Translational Sciences, Sanofi Genzyme, Cambridge, MA, USA.
Klinger K; Translational Sciences, Sanofi Genzyme, Cambridge, MA, USA.
Mistry PK; Yale Internal Medicine: Digestive Diseases, New Haven, CT, USA.